Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E4EP
|
|||
| Former ID |
DIB010284
|
|||
| Drug Name |
Oncolysin M
|
|||
| Synonyms |
Anti-CD33-bR; Anti-My9-bR
Click to Show/Hide
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Discontinued in Phase 1 | [1] | |
| Company |
Dana-Farber Cancer Institute Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Modulator | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003885) | |||
| REF 2 | US patent application no. 6,926,898, Albumin fusion proteins. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.